收费全文 | 3581篇 |
免费 | 235篇 |
国内免费 | 22篇 |
耳鼻咽喉 | 28篇 |
儿科学 | 136篇 |
妇产科学 | 90篇 |
基础医学 | 533篇 |
口腔科学 | 267篇 |
临床医学 | 278篇 |
内科学 | 672篇 |
皮肤病学 | 44篇 |
神经病学 | 404篇 |
特种医学 | 91篇 |
外科学 | 392篇 |
综合类 | 12篇 |
一般理论 | 4篇 |
预防医学 | 383篇 |
眼科学 | 47篇 |
药学 | 293篇 |
中国医学 | 38篇 |
肿瘤学 | 126篇 |
2023年 | 32篇 |
2022年 | 49篇 |
2021年 | 140篇 |
2020年 | 98篇 |
2019年 | 116篇 |
2018年 | 143篇 |
2017年 | 121篇 |
2016年 | 108篇 |
2015年 | 106篇 |
2014年 | 164篇 |
2013年 | 187篇 |
2012年 | 290篇 |
2011年 | 327篇 |
2010年 | 180篇 |
2009年 | 169篇 |
2008年 | 258篇 |
2007年 | 247篇 |
2006年 | 206篇 |
2005年 | 164篇 |
2004年 | 157篇 |
2003年 | 127篇 |
2002年 | 93篇 |
2001年 | 42篇 |
2000年 | 29篇 |
1999年 | 41篇 |
1998年 | 15篇 |
1997年 | 10篇 |
1996年 | 12篇 |
1995年 | 8篇 |
1994年 | 11篇 |
1993年 | 13篇 |
1992年 | 15篇 |
1991年 | 14篇 |
1990年 | 7篇 |
1989年 | 17篇 |
1988年 | 8篇 |
1987年 | 12篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 9篇 |
1983年 | 7篇 |
1982年 | 6篇 |
1981年 | 5篇 |
1978年 | 6篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1971年 | 3篇 |
1969年 | 3篇 |
1967年 | 5篇 |
1966年 | 3篇 |
![点击此处可从《NMR in biomedicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Background
We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.Methods
In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).Results
After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).Conclusions
This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy. 相似文献Methods: Live cell microscopy was used to visualize and measure autofluorescence of flavoproteins, a direct reporter of mitoKATP channel activity, in response to the direct and highly selective mitoKATP channel opener diazoxide, or to diazoxide following exposure to various anesthetics commonly used in experimental and clinical medicine. A cellular model of ischemia with subsequent hypoosmolar trypan blue staining served to substantiate the effects of the anesthetics on mitoKATP channels with respect to myocyte viability.
Results: Diazoxide-induced mitoKATP channel opening was significantly inhibited by the anesthetics R-ketamine, and the barbiturates thiopental and pentobarbital. Conversely, urethane, 2,2,2-trichloroethanol (main metabolite of [alpha]-chloralose and chloral hydrate), and the opioid fentanyl potentiated the channel-opening effect of diazoxide, which was abrogated by coadministration of chelerythrine, a specific protein kinase C inhibitor. S-ketamine, propofol, xylazine, midazolam, and etomidate did not affect mitoKATP channel activity. The significance of these modulatory effects of the anesthetics on mitoKATP channel activity was substantiated in a cellular model of simulated ischemia, where diazoxide-induced cell protection was mitigated by R-ketamine and the barbiturates, while urethane, 2,2,2-trichloroethanol, and fentanyl potentiated myocyte protection. 相似文献
Methods: The authors performed a double-blinded, placebo-controlled, multicenter trial to compare the effect of bisoprolol with that of placebo on 1-yr composite outcome including cardiovascular mortality, nonfatal myocardial infarction, unstable angina, congestive heart failure, and cerebrovascular insult. Bisoprolol was given orally before and after surgery for a maximum of 10 days. Adrenergic receptor polymorphisms and safety outcome measures of bisoprolol therapy were also determined.
Results: A total of 224 patients were enrolled. Spinal block could not be established in 5 patients. One hundred ten patients were assigned to the bisoprolol group, and 109 patients were assigned to the placebo group. The mean duration of treatment was 4.9 days in the bisoprolol group and 5.1 days in the placebo group. Bisoprolol therapy reduced mean heart rate by 10 beats/min. The primary outcome was identical between treatment groups and occurred in 25 patients (22.7%) in the bisoprolol group and 24 patients (22.0%) in the placebo group during the 1-yr follow-up (hazard ratio, 0.97; 95% confidence interval, 0.55-1.69; P = 0.90). However, carriers of at least one Gly allele of the [beta]1-adrenergic receptor polymorphism Arg389Gly showed a higher number of adverse events than Arg homozygous (32.4% vs. 18.7%; hazard ratio, 1.87; 95% confidence interval, 1.04-3.35; P = 0.04). 相似文献